{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:34:12Z","timestamp":1776706452867,"version":"3.51.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T00:00:00Z","timestamp":1538524800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10096-018-3389-1","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T04:11:35Z","timestamp":1538539895000},"page":"2397-2404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The association between treatment appropriateness according to EUCAST and CLSI breakpoints and mortality among patients with candidemia: a retrospective observational study"],"prefix":"10.1007","volume":"37","author":[{"given":"Nesrin","family":"Ghanem-Zoubi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Zorbavel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johad","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuval","family":"Geffen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majd","family":"Qasum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Predescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mical","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,3]]},"reference":[{"key":"3389_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1086\/421946","volume":"39","author":"H Wisplinghoff","year":"2004","unstructured":"Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309\u2013317. \n                    https:\/\/doi.org\/10.1086\/421946","journal-title":"Clin Infect Dis"},{"key":"3389_CR2","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1056\/NEJMoa022139","volume":"348","author":"GS Martin","year":"2003","unstructured":"Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of Sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546\u20131554. \n                    https:\/\/doi.org\/10.1056\/NEJMoa022139","journal-title":"N Engl J Med"},{"key":"3389_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ijantimicag.2006.01.002","volume":"27","author":"AM Tortorano","year":"2006","unstructured":"Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R (2006) Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 27:359\u2013366. \n                    https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.01.002","journal-title":"Int J Antimicrob Agents"},{"key":"3389_CR4","doi-asserted-by":"publisher","first-page":"e24198","DOI":"10.1371\/journal.pone.0024198","volume":"6","author":"M Bassetti","year":"2011","unstructured":"Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C (2011) Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One 6:e24198. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0024198","journal-title":"PLoS One"},{"key":"3389_CR5","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts. : informat","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2008","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts. : informat. Wayne, Pennsylvania 19087 USA"},{"key":"3389_CR6","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts. Fourth Inf","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2012","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2012) Reference method for broth dilution antifungal susceptibility testing of yeasts. Fourth Inf. Wayne, Pennsylvania 19087 USA"},{"key":"3389_CR7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1469-0691.2007.01935.x","volume":"14","author":"JL Rodriguez-Tudela","year":"2008","unstructured":"Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M et al (2008) EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 14:398\u2013405. \n                    https:\/\/doi.org\/10.1111\/j.1469-0691.2007.01935.x","journal-title":"Clin Microbiol Infect"},{"key":"3389_CR8","doi-asserted-by":"publisher","first-page":"E246","DOI":"10.1111\/j.1469-0691.2012.03880.x","volume":"18","author":"MC Arendrup","year":"2012","unstructured":"Arendrup MC, Cuenca-Estrella M, Lass-Fl\u00f6rl C, Hope W, EUCAST-AFST (2012) EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect 18:E246\u2013E247. \n                    https:\/\/doi.org\/10.1111\/j.1469-0691.2012.03880.x","journal-title":"Clin Microbiol Infect"},{"key":"3389_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/myc.12170","volume":"57","author":"MC Arendrup","year":"2014","unstructured":"Arendrup MC, Cuenca-Estrella M, Lass-Fl\u00f6rl C, Hope WW, European Committee on Antimicrobial Susceptibility Testing\u2014Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) (2014) EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole. Mycoses 57:377\u2013379. \n                    https:\/\/doi.org\/10.1111\/myc.12170","journal-title":"Mycoses"},{"key":"3389_CR10","unstructured":"EUCAST Antifungal Clinical Breakpoint. Table 8.1. (\n                    http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/AFST\/Clinical_breakpoints\/Antifungal_breakpoints_v_8.1_March_2017.pdf\n                    \n                  )"},{"issue":"6","key":"3389_CR11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00134-014-3310-z","volume":"40","author":"Matteo Bassetti","year":"2014","unstructured":"Bassetti M, Righi E, Ansaldi F, Merelli M, Trucchi C, Cecilia T, et al. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med 2014 8;40:839\u2013845. doi: \n                    https:\/\/doi.org\/10.1007\/s00134-014-3310-z","journal-title":"Intensive Care Medicine"},{"key":"3389_CR12","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/cid\/cis305","volume":"54","author":"M Kollef","year":"2012","unstructured":"Kollef M, Micek S, Hampton N, Doherty JA, Kumar A (2012) Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 54:1739\u20131746. \n                    https:\/\/doi.org\/10.1093\/cid\/cis305","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3389_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1086\/504810","volume":"43","author":"KW Garey","year":"2006","unstructured":"Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS et al (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43(1):25\u201331. \n                    https:\/\/doi.org\/10.1086\/504810","journal-title":"Clin Infect Dis"},{"key":"3389_CR14","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","volume":"49","author":"M Morrell","year":"2005","unstructured":"Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49:3640\u20133645. \n                    https:\/\/doi.org\/10.1128\/AAC.49.9.3640-3645.2005","journal-title":"Antimicrob Agents Chemother"},{"key":"3389_CR15","unstructured":"EUCAST-ECOFF (\n                    http:\/\/mic.eucast.org\/Eucast2\/SearchController\/search.jsp?action=init\n                    \n                  )"},{"key":"3389_CR16","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1128\/JCM.02161-10","volume":"49","author":"MA Pfaller","year":"2011","unstructured":"Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S et al (2011) Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. J Clin Microbiol 49:630\u2013637. \n                    https:\/\/doi.org\/10.1128\/JCM.02161-10","journal-title":"J Clin Microbiol"},{"key":"3389_CR17","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1128\/JCM.00248-12","volume":"50","author":"MA Pfaller","year":"2012","unstructured":"Pfaller MA, Espinel-Ingroff A, Canton E, Castanheira M, Cuenca-Estrella M, Diekema DJ et al (2012) Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 50:2040\u20132046. \n                    https:\/\/doi.org\/10.1128\/JCM.00248-12","journal-title":"J Clin Microbiol"},{"key":"3389_CR18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/1469-0691.12440","volume":"20","author":"C Orasch","year":"2014","unstructured":"Orasch C, Marchetti O, Garbino J, Schrenzel J, Zimmerli S, M\u00fchlethaler K et al (2014) Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. Clin Microbiol Infect 20:698\u2013705. \n                    https:\/\/doi.org\/10.1111\/1469-0691.12440","journal-title":"Clin Microbiol Infect"},{"key":"3389_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/myc.12553","volume":"60","author":"Y-C Chen","year":"2017","unstructured":"Chen Y-C, Kuo S-F, Chen F-J, Lee C-H (2017) Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints. Mycoses 60:89\u201395. \n                    https:\/\/doi.org\/10.1111\/myc.12553","journal-title":"Mycoses"},{"key":"3389_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.bjid.2014.06.009","volume":"18","author":"JA Cort\u00e9s","year":"2014","unstructured":"Cort\u00e9s JA, Reyes P, G\u00f3mez CH, Cuervo SI, Rivas P, Casas CA et al (2014) Clinical and epidemiological characteristics and risk factors for mortality in patients with candidemia in hospitals from Bogot\u00e1, Colombia. Braz J Infect Dis 18:631\u2013637. \n                    https:\/\/doi.org\/10.1016\/j.bjid.2014.06.009","journal-title":"Braz J Infect Dis"},{"key":"3389_CR21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/cid\/ciu407","volume":"59","author":"ND Beyda","year":"2014","unstructured":"Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW (2014) FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis 59:819\u2013825. \n                    https:\/\/doi.org\/10.1093\/cid\/ciu407","journal-title":"Clin Infect Dis"},{"key":"3389_CR22","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1093\/cid\/cit136","volume":"56","author":"BD Alexander","year":"2013","unstructured":"Alexander BD, Johnson MD, Pfeiffer CD, Jim\u00e9nez-Ortigosa C, Catania J, Booker R et al (2013) Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724\u20131732. \n                    https:\/\/doi.org\/10.1093\/cid\/cit136","journal-title":"Clin Infect Dis"},{"key":"3389_CR23","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1056\/NEJMoa066906","volume":"356","author":"AC Reboli","year":"2007","unstructured":"Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D et al (2007) Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356:2472\u20132482. \n                    https:\/\/doi.org\/10.1056\/NEJMoa066906","journal-title":"N Engl J Med"},{"key":"3389_CR24","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.4065\/83.9.1011","volume":"83","author":"A Gafter-Gvili","year":"2008","unstructured":"Gafter-Gvili A, Vidal L, Goldberg E, Leibovici L, Paul M (2008) Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 83:1011\u20131021. \n                    https:\/\/doi.org\/10.4065\/83.9.1011","journal-title":"Mayo Clin Proc"},{"key":"3389_CR25","doi-asserted-by":"publisher","first-page":"DC01","DOI":"10.7860\/JCDR\/2015\/14119.6735","volume":"9","author":"D Kumar","year":"2015","unstructured":"Kumar D, Bhattacharyya S, Gupta P, Banerjee G, Singh M (2015) Comparative analysis of disc diffusion and E-test with broth micro-dilution for susceptibility testing of clinical Candida isolates against amphotericin B, fluconazole, voriconazole and caspofungin. J Clin Diagn Res 9:DC01\u2013DC04. \n                    https:\/\/doi.org\/10.7860\/JCDR\/2015\/14119.6735","journal-title":"J Clin Diagn Res"},{"key":"3389_CR26","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.1128\/AAC.01519-13","volume":"57","author":"A Espinel-Ingroff","year":"2013","unstructured":"Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E et al (2013) Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother 57:5836\u20135842. \n                    https:\/\/doi.org\/10.1128\/AAC.01519-13","journal-title":"Antimicrob Agents Chemother"},{"key":"3389_CR27","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1128\/AAC.01256-09","volume":"54","author":"MC Arendrup","year":"2010","unstructured":"Arendrup MC, Garcia-Effron G, Lass-Fl\u00f6rl C, Lopez AG, Rodriguez-Tudela J-L, Cuenca-Estrella M et al (2010) Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother 54:426\u2013439. \n                    https:\/\/doi.org\/10.1128\/AAC.01256-09","journal-title":"Antimicrob Agents Chemother"},{"key":"3389_CR28","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","volume":"331","author":"JH Rex","year":"1994","unstructured":"Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE et al (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 331:1325\u20131330. \n                    https:\/\/doi.org\/10.1056\/NEJM199411173312001","journal-title":"N Engl J Med"},{"key":"3389_CR29","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","volume":"366","author":"B Kullberg","year":"2005","unstructured":"Kullberg B, Sobel J, Ruhnke M, Pappas P, Viscoli C, Rex J et al (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366:1435\u20131442. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(05)67490-9","journal-title":"Lancet"},{"key":"3389_CR30","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/myc.12470","volume":"59","author":"L Tadec","year":"2016","unstructured":"Tadec L, Talarmin J-P, Gastinne T, Bretonni\u00e8re C, Miegeville M, Le Pape P et al (2016) Epidemiology, risk factor, species distribution, antifungal resistance and outcome of candidemia at a single French hospital: a 7-year study. Mycoses 59:296\u2013303. \n                    https:\/\/doi.org\/10.1111\/myc.12470","journal-title":"Mycoses"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-018-3389-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-018-3389-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-018-3389-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T23:10:40Z","timestamp":1570057840000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-018-3389-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,3]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3389"],"URL":"https:\/\/doi.org\/10.1007\/s10096-018-3389-1","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,3]]},"assertion":[{"value":"27 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee at Rambam Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not required; not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}